Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Safety and Activity of HF50 in Patients With Advanced Solid Tumors

23 de septiembre de 2026 actualizado por: HighField Biopharmaceuticals Corporation

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of HF50 in Patients With Advanced Solid Tumors

A study to assess the safety, tolerability, and pharmacokinetics of HF50 in participants with advanced solid tumors.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

This is an open-label, dose-escalation and dose-expansion, multiple-dose, phase 1 study evaluating HF50 monotherapy in participants with advanced solid tumors. HF50 is an innovative liposome-encapsulated T-cell engager designed to redirect T-cells to tumor cells by presenting both tumor-associated antigen (e.g., HER2) and CD3 targeting moieties on the liposome surface. Simultaneously, HF50 delivers an encapsulated TLR7/8 agonist to activate innate immunity and remodel the tumor immune microenvironment, creating a synergistic anti-tumor immune response.The primary objective is to evaluate the safety and tolerability of HF50 and to determine the recommended Phase 2 dose (RP2D). HF50 will be administered as an intravenous (IV) infusion. The study will also assess the pharmacokinetic (PK) profile, immunogenicity, and preliminary anti-tumor activity of HF50. Additionally, the study will explore the impact of HF50 on the immune microenvironment and changes in peripheral blood cytokines and immune cells to better understand its biological effects.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

45

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100021
        • Aún no reclutando
        • Cancer Hospital, Chinese Academy of Medical Sciences
        • Contacto:
          • FEI MA, MD,PhD
        • Investigador principal:
          • FEI MA, MD,PhD
    • Guangdong
      • Guangzhou, Guangdong, Porcelana, 510120
        • Reclutamiento
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
        • Investigador principal:
          • Jing Li, MD, PhD
        • Investigador principal:
          • Qiong Yang, MD, PhD
        • Contacto:
          • HERUI YAO, MD,PhD
          • Número de teléfono: +8613500018020
          • Correo electrónico: yaohrsysu@163.com
        • Investigador principal:
          • HERUI YAO, MD,PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Voluntary participation: Capable of giving signed informed consent and able to comply with all study-related procedures.
  • Age: Adults >= 18 years of age at the time of signing informed consent; male or female.
  • Disease Status: Participants with histologically or cytologically confirmed advanced solid tumors that are unresectable or metastatic, who have failed or are intolerant to standard therapies, or for whom no effective therapy currently exists. Examples include HER2-expressing gynecological tumors and recurrent ovarian clear cell carcinoma after failure of platinum-based chemotherapy.
  • Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
  • Life Expectancy: Anticipated survival of no less than 6 months.
  • Measurable Disease: At least one measurable lesion according to RECIST v1.1 definitions.
  • Organ and Bone Marrow Function:

Bone Marrow Reserve: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L, lymphocyte count >= 1.0 x 10^9/L, platelet count >= 90 x 10^9/L, and hemoglobin >= 9.0 g/dL (no blood transfusion or hematopoietic stimulators within 14 days).

Coagulation Function: Activated partial thromboplastin time (APTT) <= 1.5 x ULN, and International Normalized Ratio (INR) <= 1.5.

Liver Function: Total bilirubin (TBIL) <= 1.5 x ULN, and ALT and AST <= 2.5 x ULN. For participants with liver metastases: ALT and AST <= 5 x ULN, and TBIL <= 3 x ULN.

Renal Function: Creatinine clearance >= 50 mL/min (calculated using the Cockcroft-Gault formula).

  • Contraception: Participants of reproductive potential (including males) must agree to use effective contraception from study entry through 6 months after the last dose. Female participants of childbearing potential must have a negative serum pregnancy test during screening and prior to the first dose.

Exclusion Criteria:

  • Autoimmune Disease: Any active autoimmune disease or history of autoimmune disease deemed unsuitable by the investigator. Exceptions include skin conditions not requiring systemic treatment (e.g., eczema < 10% of body surface area, vitiligo, psoriasis, alopecia) and resolved childhood asthma.
  • Corticosteroids/Immunosuppressants: Current use of immunosuppressants or systemic corticosteroids (> 10 mg/day prednisone or equivalent) within 4 weeks prior to the first dose. Topical steroid use is permitted.
  • Prior Anti-tumor Therapy: Receipt of systemic chemotherapy, radiotherapy, targeted therapy, or immunotherapy within 2 weeks prior to dosing (4 weeks for nitrosoureas or mitomycin C); or other therapies (endocrine therapy, TCM, localized palliative radiotherapy) within 2 weeks.
  • CNS Metastasis: Clinically symptomatic brain or meningeal metastases. Participants with treated brain metastases are eligible if radiographic stability is maintained for >= 28 days, systemic steroids have been discontinued for > 14 days, and the participant is asymptomatic.
  • Toxicity Recovery: Failure to recover from all adverse events of prior therapies to <= Grade 1 (NCI CTCAE v5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, or stable hypothyroidism on hormone replacement.
  • Cardiovascular History: Including thromboembolic events within 3 months; NYHA Class III to IV congestive heart failure; acute coronary syndrome, aortic dissection, stroke, or other Grade >= 3 cardiovascular events within 6 months; or uncontrolled hypertension (SBP > 160 mmHg or DBP > 100 mmHg).
  • Infection: Active infection or unexplained fever > 38.5 degrees C within 1 week prior to the first dose (tumor-related fever is permitted per investigator judgment).
  • Viral Infection: HIV infection, active HBV (HBV DNA > ULN), or active HCV (HCV RNA > ULN).
  • Gastrointestinal Symptoms: Significant digestive system symptoms or other factors requiring intervention within 4 weeks prior to the first dose.
  • Pregnancy/Lactation: Female participants who are pregnant or breastfeeding.
  • Other: Any other serious systemic disease or reason that, in the investigator's opinion, makes the participant unsuitable for the study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: HF50

HF50 monotherapy

HF50 is an innovative liposome-encapsulated bifunctional therapeutic designed to redirect T-cells to HER2-expressing tumor cells while simultaneously activating innate immunity through TLR7/8 agonism.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants with Dose Limiting Toxicities (DLT)
Periodo de tiempo: 28 days after the first dose (C1D1) for each dose cohort.

The number of participants experiencing dose-limiting toxicities (DLTs) during the DLT evaluation period to determine the maximum tolerated dose (MTD).

28 days after the first dose (C1D1) for each dose cohort.
Incidence of Adverse Events (AEs)
Periodo de tiempo: From first dose to 28 days after the last dose.

The number and percentage of participants experiencing adverse events (AEs), graded according to NCI-CTCAE v5.0

From first dose to 28 days after the last dose.
Recommended Phase II Dose (RP2D) of HF50
Periodo de tiempo: At the end of dose escalation (assessed up to 1 year)

RP2D will be determined based on safety, tolerability, and pharmacokinetics data collected during the dose escalation phase.

At the end of dose escalation (assessed up to 1 year)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Objective Response Rate (ORR)
Periodo de tiempo: Up to 2 years

Proportion of participants achieving a complete response (CR) or partial response (PR) based on RECIST v1.1 criteria.

Up to 2 years
Duration of Response (DOR)
Periodo de tiempo: Up to 2 years

Time from the first documented response (CR or PR) to disease progression or death.

Up to 2 years
Disease Control Rate (DCR)
Periodo de tiempo: Up to 2 years

Proportion of participants achieving CR, PR, or stable disease (SD) based on RECIST v1.1.

Up to 2 years
Progression-Free Survival (PFS)
Periodo de tiempo: Up to 2 years

Time from the first dose to disease progression or death.

Up to 2 years
Overall Survival (OS)
Periodo de tiempo: Up to 2 years

Time from the first dose to death from any cause.

Up to 2 years
Pharmacokinetic Parameter - Cmax
Periodo de tiempo: Up to 2 years

Maximum plasma concentration (Cmax) of HF50 will be assessed following single and multiple dosing.

Up to 2 years
Pharmacokinetic Parameter - Tmax
Periodo de tiempo: Up to 2 years

Time to maximum plasma concentration (Tmax) of HF50 will be assessed following single and multiple dosing.

Up to 2 years
Pharmacokinetic Parameter - AUC (Area Under the Curve)
Periodo de tiempo: Up to 2 years

AUC0-t and AUC0-inf will be evaluated to determine systemic exposure to HF50.

Up to 2 years
Pharmacokinetic Parameter - Half-life (t1/2)
Periodo de tiempo: Up to 2 years

The terminal elimination half-life (t1/2) of HF50 will be calculated.

Up to 2 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: HERUI YAO, MD,PhD, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

8 de septiembre de 2026

Finalización primaria (Estimado)

30 de junio de 2028

Finalización del estudio (Estimado)

30 de junio de 2029

Fechas de registro del estudio

Enviado por primera vez

15 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

15 de mayo de 2026

Publicado por primera vez (Actual)

22 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

28 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

23 de septiembre de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • HF50-102

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .